Project Summary
Approximately 33% of the nearly 700 workplace chemicals identified in the National Institute of Occupational
Safety and Health (NIOSH) Pocket Guide are associated with hepatotoxicity. Several of these have been linked
to increased liver disease mortality in workers in different occupational settings such as heavy construction
equipment operators, chimney sweepers, and chemical workers. Xenobiotic-induced hepatotoxicity is
characterized by oxidative stress, inflammation, and fibrosis, which, in later stages, may result in hepatic failure
and hepatocellular carcinoma (HCC). While transcriptional perturbations have been implicated in inflammation
and fibrosis; the role of post-transcriptional regulation in the development of xenobiotic-induced hepatic
inflammation and fibrosis is unclear. The tristetraprolin (TTP) family of RNA binding proteins (RBPs)
including zinc finger protein 36 (ZFP36) commonly referred to as TTP, zinc finger protein 36 like 1 (ZFP36L1),
and zinc finger protein 36 like 2 (ZFP36L2), are the key players in post-transcriptional regulation of a large
number of inflammation-relevant mRNAs. These proteins bind to AU-rich elements (AREs) on the 3’untranslated
regions (3’UTRs) of target mRNAs and promote their decay. TTP family RBPs are dysregulated in human HCC.
Industrial chemicals including chlorpyrifos, tetrachlorodibenzo-p-dioxin (TCDD), and carbon tetrachloride (CCl4),
also dysregulate the expression of TTP family RBPs. However, the downstream molecular and cellular effects
of these dysregulations on the host remain unknown. In this proposal, we will test our novel hypothesis that
xenobiotic-induced dysregulation of TTP family RBPs expression results in altered post-transcriptional regulation
that determines the pathogenesis of hepatic inflammation and fibrosis. We will use CCl4-induced liver
inflammation and fibrosis as a model of hepatotoxicity and test our hypothesis through three specific aims. In
Aim 1, we will employ liver-specific ablations of the three RBPs in mice and novel “omics” approaches to test the
pathogenic mechanisms by which these RBPs regulate xenobiotic-induced liver inflammation and fibrosis. Aim
2 will characterize the cellular and molecular mechanisms by which TTP family RBPs regulate epithelial-
mesenchymal transition, a lead cause of fibrosis and tumor metastasis, and finally, Aim 3 will test whether
increasing the expression of TTP family RBPs in the liver protects against xenobiotic-induced hepatic
inflammation and fibrosis. The overall goal of the proposed research is to understand the role of TTP family RBP
mediated post-transcriptional regulation in the pathogenesis of xenobiotic-induced hepatotoxicity. Successful
completion of the proposed studies will have a significant impact on the mechanistic understanding of the
pathophysiology of xenobiotic-induced liver disease and the potential identification of TTP family RBPs as
endogenous anti-inflammatory/anti-fibrotic proteins whose activity could be possibly enhanced to delay or
prevent the onset of liver failure.